Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

Figure 1 Study design. DP: Docetaxel/cisplatin; EGFR: Epithelial growth factor receptor; PD: Progressive disease; PP: Pemetrexed/cisplatin; PR: Partial response; SD: Stable disease.

Figure 2 Progression-free survival of patients. A: Progression-free survival (PFS) with icotinib vs chemotherapy followed by icotinib; B: PFS with two-cycle chemotherapy followed by icotinib vs four-cycle chemotherapy followed by icotinib; C: PFS with DP followed by icotinib vs PP followed by icotinib; D: PFS with icotinib vs various chemotherapy regimens followed by icotinib. DP: Docetaxel/cisplatin; PP: Pemetrexed/cisplatin.

Figure 3 Overall survival of patients. A: Overall survival (OS) with icotinib vs chemotherapy followed by icotinib; B: OS with two-cycle chemotherapy followed by icotinib vs four-cycle chemotherapy followed by icotinib; C: OS with docetaxel/cisplatin followed by icotinib vs PP followed by icotinib; D: OS with icotinib vs various chemotherapy regimens followed by icotinib. DP: Docetaxel/cisplatin; PP: Pemetrexed/cisplatin.